Frequent horizontal and mother-to-child transmission may contribute to high prevalence of STLV-1 infection in Japanese macaques.
Animals
Antibodies, Viral
/ blood
Deltaretrovirus Infections
/ transmission
Disease Transmission, Infectious
Female
Follow-Up Studies
Infectious Disease Transmission, Vertical
Japan
Macaca fuscata
/ virology
Male
Prevalence
Proviruses
/ genetics
Seroepidemiologic Studies
Simian T-lymphotropic virus 1
/ genetics
Antibody titer
Horizontal transmission
Japanese macaques
Mother-to-child transmission
Prevalence
Proviral load
STLV-1
Journal
Retrovirology
ISSN: 1742-4690
Titre abrégé: Retrovirology
Pays: England
ID NLM: 101216893
Informations de publication
Date de publication:
23 06 2020
23 06 2020
Historique:
received:
11
04
2020
accepted:
16
06
2020
entrez:
25
6
2020
pubmed:
25
6
2020
medline:
11
3
2021
Statut:
epublish
Résumé
Simian T-cell leukemia virus type 1 (STLV-1) is disseminated among various non-human primate species and is closely related to human T-cell leukemia virus type 1 (HTLV-1), the causative agent of adult T-cell leukemia and HTLV-1-associated myelopathy/tropical spastic paraparesis. Notably, the prevalence of STLV-1 infection in Japanese macaques (JMs) is estimated to be > 60%, much greater than that in other non-human primates; however, the mechanism and mode of STLV-1 transmission remain unknown. The aim of this study is to examine the epidemiological background by which STLV-1 infection is highly prevalent in JMs. The prevalence of STLV-1 in the JMs rearing in our free-range facility reached up to 64% (180/280 JMs) with variation from 55 to 77% among five independent troops. Anti-STLV-1 antibody titers (ABTs) and STLV-1 proviral loads (PVLs) were normally distributed with mean values of 4076 and 0.62%, respectively, which were mostly comparable to those of HTLV-1-infected humans. Our initial hypothesis that some of the macaques might contribute to frequent horizontal STLV-1 transmission as viral super-spreaders was unlikely because of the absence of the macaques exhibiting abnormally high PVLs but poor ABTs. Rather, ABTs and PVLs were statistically correlated (p < 0.0001), indicating that the increasing PVLs led to the greater humoral immune response. Further analyses demonstrated that the STLV-1 prevalence as determined by detection of the proviral DNA was dramatically increased with age; 11%, 31%, and 58% at 0, 1, and 2 years of age, respectively, which was generally consistent with the result of seroprevalence and suggested the frequent incidence of mother-to-child transmission. Moreover, our longitudinal follow-up study indicated that 24 of 28 seronegative JMs during the periods from 2011 to 2012 converted to seropositive (86%) 4 years later; among them, the seroconversion rates of sexually matured (4 years of age and older) macaques and immature macaques (3 years of age and younger) at the beginning of study were comparably high (80% and 89%, respectively), suggesting the frequent incidence of horizontal transmission. Together with the fact that almost all of the full-adult JMs older than 9 years old were infected with STLV-1, our results of this study demonstrated for the first time that frequent horizontal and mother-to-child transmission may contribute to high prevalence of STLV-1 infection in JMs.
Sections du résumé
BACKGROUND
Simian T-cell leukemia virus type 1 (STLV-1) is disseminated among various non-human primate species and is closely related to human T-cell leukemia virus type 1 (HTLV-1), the causative agent of adult T-cell leukemia and HTLV-1-associated myelopathy/tropical spastic paraparesis. Notably, the prevalence of STLV-1 infection in Japanese macaques (JMs) is estimated to be > 60%, much greater than that in other non-human primates; however, the mechanism and mode of STLV-1 transmission remain unknown. The aim of this study is to examine the epidemiological background by which STLV-1 infection is highly prevalent in JMs.
RESULTS
The prevalence of STLV-1 in the JMs rearing in our free-range facility reached up to 64% (180/280 JMs) with variation from 55 to 77% among five independent troops. Anti-STLV-1 antibody titers (ABTs) and STLV-1 proviral loads (PVLs) were normally distributed with mean values of 4076 and 0.62%, respectively, which were mostly comparable to those of HTLV-1-infected humans. Our initial hypothesis that some of the macaques might contribute to frequent horizontal STLV-1 transmission as viral super-spreaders was unlikely because of the absence of the macaques exhibiting abnormally high PVLs but poor ABTs. Rather, ABTs and PVLs were statistically correlated (p < 0.0001), indicating that the increasing PVLs led to the greater humoral immune response. Further analyses demonstrated that the STLV-1 prevalence as determined by detection of the proviral DNA was dramatically increased with age; 11%, 31%, and 58% at 0, 1, and 2 years of age, respectively, which was generally consistent with the result of seroprevalence and suggested the frequent incidence of mother-to-child transmission. Moreover, our longitudinal follow-up study indicated that 24 of 28 seronegative JMs during the periods from 2011 to 2012 converted to seropositive (86%) 4 years later; among them, the seroconversion rates of sexually matured (4 years of age and older) macaques and immature macaques (3 years of age and younger) at the beginning of study were comparably high (80% and 89%, respectively), suggesting the frequent incidence of horizontal transmission.
CONCLUSIONS
Together with the fact that almost all of the full-adult JMs older than 9 years old were infected with STLV-1, our results of this study demonstrated for the first time that frequent horizontal and mother-to-child transmission may contribute to high prevalence of STLV-1 infection in JMs.
Identifiants
pubmed: 32576215
doi: 10.1186/s12977-020-00525-1
pii: 10.1186/s12977-020-00525-1
pmc: PMC7310504
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
15Subventions
Organisme : Japan Agency for Medical Research and Development
ID : 19cm0106365s0101
Pays : International
Organisme : Japan Agency for Medical Research and Development
ID : 18fk0108059h0201
Pays : International
Références
Cancer Res. 1987 Jan 1;47(1):269-74
pubmed: 2878717
Virology. 1998 Apr 10;243(2):366-79
pubmed: 9568035
Curr Opin Ophthalmol. 2012 Nov;23(6):557-61
pubmed: 23047174
Int J Cancer. 1984 Feb 15;33(2):179-83
pubmed: 6319300
Sleep Med Rev. 2000 Aug;4(4):355-373
pubmed: 12531175
J Gen Virol. 1998 Jan;79 ( Pt 1):51-5
pubmed: 9460922
Virology. 1994 Jan;198(1):297-310
pubmed: 8259665
Br J Haematol. 1991 Nov;79(3):428-37
pubmed: 1751370
PLoS Negl Trop Dis. 2012;6(6):e1690
pubmed: 22720106
Virology. 1985 Jul 15;144(1):59-65
pubmed: 2998047
Lancet Oncol. 2014 Oct;15(11):e517-26
pubmed: 25281470
Clin Microbiol Rev. 2010 Jul;23(3):577-89
pubmed: 20610824
Lancet. 1986 May 3;1(8488):1031-2
pubmed: 2871307
Lancet. 1983 Oct 22;2(8356):962-3
pubmed: 6138516
J Virol. 1996 Mar;70(3):1633-9
pubmed: 8627684
Front Microbiol. 2012 Nov 15;3:388
pubmed: 23162541
Retrovirology. 2019 Dec 16;16(1):41
pubmed: 31843020
Sci Rep. 2015 Mar 06;5:8850
pubmed: 25743183
Jpn J Cancer Res. 1997 Jan;88(1):1-4
pubmed: 9045888
Nature. 2010 Jul 15;466(7304):302-3
pubmed: 20631767
Curr Opin Virol. 2015 Oct;14:93-100
pubmed: 26414684
J Gen Virol. 1993 Nov;74 ( Pt 11):2531-7
pubmed: 8245871
Blood. 1977 Sep;50(3):481-92
pubmed: 301762
Int J Cancer. 1998 May 4;76(3):331-6
pubmed: 9579568
Virus Evol. 2016 May 25;2(1):vew011
pubmed: 27774304
J Virol. 2002 Jan;76(1):259-68
pubmed: 11739691
Lancet. 1985 Aug 24;2(8452):407-10
pubmed: 2863442
Emerg Microbes Infect. 2014 Jan;3(1):e7
pubmed: 26038495
Int J Cancer. 1990 Feb 15;45(2):237-43
pubmed: 2303290
J Virol. 1997 May;71(5):3684-92
pubmed: 9094642
AIDS Res Hum Retroviruses. 1994 Sep;10(9):1135-42
pubmed: 7826698
Virology. 1994 Feb 15;199(1):56-66
pubmed: 8116255
Cancer Lett. 2017 Mar 28;389:78-85
pubmed: 28034804
J Virol. 1994 Apr;68(4):2693-707
pubmed: 7908063
Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9
pubmed: 6261256
AIDS. 2012 Mar 27;26(6):659-73
pubmed: 22441170
Nagoya J Med Sci. 1991 Mar;53(1-4):23-32
pubmed: 1805134
Int J Cancer. 1983 Sep 15;32(3):333-6
pubmed: 6411631
J Med Virol. 2018 Feb;90(2):351-357
pubmed: 28876483
J Emerg Med. 2000 Jan;18(1):109-19
pubmed: 10645850
Handb Clin Neurol. 2014;123:507-30
pubmed: 25015502
Microbiol Immunol. 1983;27(3):297-301
pubmed: 6603569
Am J Primatol. 2003 Mar;59(3):123-8
pubmed: 12619046
J Med Virol. 2012 Feb;84(2):327-35
pubmed: 22170555
J Virol. 2002 Feb;76(4):1642-8
pubmed: 11799159
Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):1124-7
pubmed: 8302841
Int J Cancer. 1987 Aug 15;40(2):233-9
pubmed: 2440820
J Gen Virol. 2001 Dec;82(Pt 12):2973-2977
pubmed: 11714973
J Virol. 2003 Jan;77(1):782-9
pubmed: 12477886
PLoS One. 2017 Apr 6;12(4):e0174920
pubmed: 28384180
Genome Res. 1999 Jun;9(6):525-40
pubmed: 10400920
Mol Biol Evol. 2004 Mar;21(3):603-11
pubmed: 14739252
Lancet. 1986 Aug 16;2(8503):397-8
pubmed: 2874393
J Virol. 2017 Apr 28;91(10):
pubmed: 28298599
J Med Virol. 2005 Jul;76(3):386-90
pubmed: 15902707
Retrovirology. 2013 Oct 24;10:118
pubmed: 24156738
Int J Cancer. 1988 Apr 15;41(4):601-8
pubmed: 2895751
J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jun 1;12(2):187-92
pubmed: 8680891
Nat Rev Dis Primers. 2015 Jun 18;1:15012
pubmed: 27188208
J Clin Virol. 2010 Jun;48(2):155-7
pubmed: 20395170
AIDS Res Hum Retroviruses. 2011 Feb;27(2):113-4
pubmed: 20854200
J Med Virol. 2010 Dec;82(12):2116-22
pubmed: 20981802
J Virol. 2004 May;78(9):4700-9
pubmed: 15078952
Clin Infect Dis. 2015 Jun 1;60(11):1667-76
pubmed: 25722199
J Med Primatol. 2009 Jun;38(3):160-70
pubmed: 19320800
Retrovirology. 2005 Mar 02;2:16
pubmed: 15743528
Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5
pubmed: 6979048
J Infect Dis. 2015 Feb 1;211(3):361-5
pubmed: 25147276
AIDS Res Hum Retroviruses. 1998 Mar 1;14(4):367-71
pubmed: 9519898